/LYEL
LYEL Stock - Lyell Immunopharma, Inc.
Healthcare|BiotechnologyNASDAQ
$33.33+2.93%
+$0.95 (+2.93%) • Dec 19
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).45
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-2.5%upside
Target: $32.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LYEL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$33.00 – $33.66
TARGET (TP)$32.50
STOP LOSS$30.66
RISK/REWARD1:-0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.11
52W High$35.16
52W Low$7.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $61,000 | $130,000 | $84.68M | $10.65M | $7.76M |
| Gross Profit | $61,000 | $130,000 | $84.68M | $10.65M | $7.76M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-358,755,000 | $-247,008,000 | $-187,058,000 | $-214,776,000 | $-211,937,000 |
| Net Income | $-342,994,000 | $-234,632,000 | $-183,118,000 | $-250,219,000 | $-204,472,000 |
| Net Margin | -562285.2% | -180486.2% | -216.2% | -2349.5% | -2636.3% |
| EPS | $-1.31 | $-0.93 | $-0.74 | $-1.03 | $-0.84 |
Company Overview
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
29%
Hold / Neutral
4
57%
Sell / Underperform
1
14%
Analyst Consensus🔴 Bearish
2 Bullish5 Neutral/Bearish
Price Targets
$11
Average Target
↓ 66.6% Downside
Now
$1
Low
$11
Average
$45
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | H.C. Wainwright | Upgrade | Buy | $45 |
| October 30th 2024 | BofA Securities | Downgrade | Underperform | $1← $6 |
| June 27th 2024 | H.C. Wainwright | Downgrade | Neutral | $1← $6 |
| August 28th 2023 | JP Morgan | Downgrade | Neutral | $5← $15 |
| November 14th 2022 | Morgan Stanley | Downgrade | Equal Weight | $7← $15 |
| November 11th 2022 | Goldman | Downgrade | Neutral | $7← $13 |
| October 17th 2022 | H.C. Wainwright | Initiation | Buy | $12 |
Earnings History & Surprises
LYELBeat Rate
83%
Last 18 quarters
Avg Surprise
-6.5%
EPS vs Estimate
Beats / Misses
15/3
Last 12 quarters
Latest EPS
$-2.13
Q4 2025
EPS Surprise History
Q1 24
+4.8%
$-0.20vs$-0.21
Q2 24
-20.0%
$-0.24vs$-0.20
Q3 24
+10.0%
$-0.18vs$-0.20
Q4 24
+15.0%
$-0.17vs$-0.20
Q1 25
-300.0%
$-0.72vs$-0.18
Q2 25
+5.3%
$-3.60vs$-3.80
Q3 25
+23.9%
$-2.89vs$-3.80
Q4 25
+24.2%
$-2.13vs$-2.81
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 10, 2026 | $-3.02 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-2.81 | $-2.13 | +24.2% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-3.80 | $-2.89 | +23.9% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-3.80 | $-3.60 | +5.3% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $-0.18 | $-0.72 | -300.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.20 | $-0.18 | +10.0% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-0.21 | $-0.20 | +4.8% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.27 | $-0.20 | +25.9% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.30 | $-0.26 | +13.3% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.28 | $-0.27 | +3.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.31 | $-0.03 | +90.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.34 | $-0.28 | +17.6% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.31 | $-0.15 | +51.6% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-0.29 | $-0.28 | +3.4% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.28 | $-0.18 | +35.7% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.27 | $-0.20 | +25.9% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.36 | $-0.89 | -147.2% | ✗ MISS |
Q2 2021 | Jun 18, 2021 | — | $-0.18 | — | — |
Latest News
HC Wainwright & Co. Upgrades Lyell Immunopharma to Buy, Raises Price Target to $45
📈 PositiveBenzinga•Dec 9, 2025, 11:30 AM
Reported Sunday, Lyell Reports Ronde-Cel Shows High Durable Complete Responses In LBCL With 93% ORR And 76% CR In 3L+ Setting At ASH 2025
📈 PositiveBenzinga•Dec 8, 2025, 08:21 AM
Lyell Immunopharma Files For Proposed Resale From Time To Time By Innovative Cellular Therapeutics Holdings Limited Of Up To 1.9M Shares
➖ NeutralBenzinga•Dec 5, 2025, 09:41 PM
Lyell Immunopharma shares are trading higher after HC Wainwright maintained a Neutral rating on the stock and raised its price target from $10 to $20.
📈 PositiveBenzinga•Nov 24, 2025, 04:18 PM
HC Wainwright & Co. Maintains Neutral on Lyell Immunopharma, Raises Price Target to $20
➖ NeutralBenzinga•Nov 24, 2025, 12:53 PM
Lyell Immunopharma Q3 Sales $15.000K Down From $34.000K YoY
📉 NegativeBenzinga•Nov 12, 2025, 09:47 PM
Lyell Immunopharma Acquires Exclusive Global Rights To LYL273, In Clinical Development For Metastatic Colorectal Cancer From Innovative Cellular Therapeutics (ICT); ICT To Receive $40M And 1.9M Shares Of Lyell Stock As Well As Milestones Up to $675M
📈 PositiveBenzinga•Nov 10, 2025, 12:34 PM
Lyell Immunopharma To Present Two Abstracts Highlighting New Clinical And Translational Data From Phase 1/2 Clinical Trial Of Rondecabtagene Autoleucel For Treatment Of Aggressive LBCL At ASH 2025
📈 PositiveBenzinga•Nov 3, 2025, 02:02 PM
Lyell Immunopharma Appoints CEO Lynn Seely As Interim CFO And Veronica Sanchez Bulis As Principal Accounting Officer
➖ NeutralBenzinga•Nov 3, 2025, 01:44 PM
LUCID CAPITAL MARKETS Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $20
📈 PositiveBenzinga•Sep 26, 2025, 11:22 AM•Also:
Lyell Immunopharma CFO Charles Newton To Resign Effective October 31, 2025
📉 NegativeBenzinga•Sep 16, 2025, 08:24 PM
Lyell Immunopharma Initiates Pinacle - H2H, Phase 3 Head-To-Head CAR T-Cell Therapy Randomized Controlled Trial; Forms Steering Committee Of Preeminent Lymphoma Experts
📈 PositiveBenzinga•Sep 3, 2025, 12:10 PM
Lyell Immunopharma Initiates Phase 3 Head-to-Head CAR T-Cell Therapy Trial Evaluating LYL314
📈 PositiveBenzinga•Sep 3, 2025, 12:09 PM
Lyell Immunopharma announces up to $100 million equity private placement
📈 PositiveSeeking Alpha•Jul 25, 2025, 12:35 PM
Frequently Asked Questions about LYEL
What is LYEL's current stock price?
Lyell Immunopharma, Inc. (LYEL) is currently trading at $33.33 per share. The stock has moved +2.93% today.
What is the analyst price target for LYEL?
The average analyst price target for LYEL is $32.50, based on 1 analyst.
What sector is Lyell Immunopharma, Inc. in?
Lyell Immunopharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LYEL's market cap?
Lyell Immunopharma, Inc. has a market capitalization of $0.71 billion, making it a small-cap company.
Does LYEL pay dividends?
No, Lyell Immunopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to LYEL for comparison